Evermay Wealth Management LLC Trims Holdings in Edwards Lifesciences Co. (NYSE:EW)

Evermay Wealth Management LLC reduced its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 23.7% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 2,574 shares of the medical research company’s stock after selling 798 shares during the period. Evermay Wealth Management LLC’s holdings in Edwards Lifesciences were worth $191,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. FSA Wealth Management LLC acquired a new stake in Edwards Lifesciences in the third quarter valued at approximately $30,000. Prospera Private Wealth LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $32,000. Avior Wealth Management LLC grew its position in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the period. Peoples Bank KS purchased a new stake in shares of Edwards Lifesciences during the third quarter worth about $40,000. Finally, Roble Belko & Company Inc acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth about $46,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Robert W. Baird decreased their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Barclays lifted their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a report on Monday, December 2nd. Truist Financial restated a “hold” rating and set a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. JPMorgan Chase & Co. boosted their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Finally, Canaccord Genuity Group raised their price target on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a report on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $79.19.

Insiders Place Their Bets

In other news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 33,000 shares of company stock worth $2,195,180. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Price Performance

Shares of EW opened at $72.41 on Friday. The firm has a market capitalization of $42.71 billion, a PE ratio of 10.45, a P/E/G ratio of 3.65 and a beta of 1.11. The stock’s 50 day moving average is $72.49 and its two-hundred day moving average is $69.97. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.